IntrinsicIntrinsic
← All summaries

Protagonist Therapeutics, Inc

PTGX
Financials & Chart →

Business Summary

Protagonist Therapeutics, Inc. is an integrated discovery and development company with a validated technology platform operating in three broad therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. The company aims to develop medicines for biologically and commercially validated targets that demonstrate strong differentiation compared to existing therapies.

The company faces intense competition from established and emerging pharmaceutical and biotechnology companies, academic institutions, and research organizations. In psoriasis and psoriatic arthritis, competitors include Cosentyx (Novartis), Taltz (Eli Lilly), Siliq (Bausch Health), Tremfya (Johnson & Johnson), Skyrizi (AbbVie), Bimzelx (UCB), Otezla (Amgen), Xeljanz (Pfizer), Rinvoq (AbbVie), and Sotyktu (Bristol Myers Squibb). In inflammatory bowel disease, competition includes Entyvio (Takeda), Stelara (Johnson & Johnson), Skyrizi (AbbVie), Tremfya (Johnson & Johnson), Omvoh (Eli Lilly), Xeljanz, Rinvoq, Zeposia, and Velsipity. In polycythemia vera, competition includes Jakafi (Incyte), Besremi (PharmaEssentia/AOP), bomedemstat (Merck/Imago), givinostat (Italfarmaco), divesiran (Silence Therapeutics), DISC-3405 (Disc Medicine), sapablursen (Ionis Pharmaceuticals), and vamifeport (CSL Vifor). In obesity, competition includes Wegovy (Novo Nordisk), Zepbound (Eli Lilly), retatrutide (Eli Lilly), CagriSema (Novo Nordisk), MariTide (Amgen), VK2735 (Viking Therapeutics), orforglipron (Eli Lilly), aleniglipron (Structure Therapeutics), amycretin (Novo Nordisk), petrelintide (Zealand Pharma/Roche), survodutide (Boehringer Ingelheim), and pemvidutide (Altimmune).

The company generates revenue through license and collaboration agreements with partners, primarily Janssen Biotech, Inc. (a Johnson & Johnson company) and Takeda Pharmaceuticals USA, Inc. Revenue is derived from upfront payments, milestone payments, development service fees, and potential future royalties on product sales. The company has no approved products and no historical commercial revenue from product sales.

Icotyde (icotrokinra) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor, licensed to JNJ under a license and collaboration agreement initially entered into in 2017. JNJ submitted a New Drug Application to the FDA in July 2025 and an application to the European Medicines Agency in September 2025 seeking first approval for moderate-to-severe plaque psoriasis. The company has earned a total of $337.5 million in milestone payments from JNJ under the agreement, including a $165.0 million milestone payment earned in the fourth quarter of 2024. The company is eligible to receive up to $630.0 million in future development and sales milestone payments, and will receive upward tiering royalties on net worldwide Icotyde product sales at percentages ranging from 6% to 10% , with a weighted average royalty rate on the first $4.0 billion in annual net sales of 7.25% and a rate on net sales over $4.0 billion of 10% . Rusfertide is a first-in-class investigational injectable mimetic of the natural hormone hepcidin in development for polycythemia vera, partnered with Takeda under a license and collaboration agreement entered into in January 2024. The company received an upfront payment of $300.0 million in April 2024 and a $25.0 million milestone payment in September 2025 upon completion of the Phase 3 VERIFY clinical trial report. Under the Takeda Collaboration Agreement, the company and Takeda share equally in profits and losses (50% to the company and 50% to Takeda) associated with rusfertide in the United States, and the company will receive tiered royalties ranging from 10% to 17% on ex-U.S. net sales. The company has the right to opt-out of the U.S. profit and loss sharing arrangement, and if exercised, will receive royalties of 14% to 29% on annual worldwide net sales, with a weighted average royalty rate of 21% at $1.5 billion in net sales and a rate of 29% for net sales over $1.5 billion . The company is eligible to receive up to an aggregate of $975.0 million in development, regulatory and sales milestones, including the $25.0 million milestone payment already received, and up to $400.0 million in payments for exercising the opt-out right. PN-881 is a wholly owned oral peptide IL-17 antagonist; in October 2025, the first human subject was dosed in a Phase 1 trial. PN-477 is a novel triple GLP-1, GIP and GCG receptor agonist peptide nominated as a development candidate in June 2025 for obesity. PN-458 is a novel dual GLP-1 and GIP receptor agonist peptide nominated as a development candidate in December 2025 for obesity. PN-8047 is an orally administered hepcidin functional mimetic small molecule nominated as a development candidate in December 2025.

In April 2023, the company completed an underwritten public offering of 5,000,000 shares of common stock at a public offering price of $20.00 per share and issued an additional 750,000 shares at $20.00 per share following the underwriters' exercise of their option, with net proceeds of approximately $107.8 million . In August 2022, the company entered into an Open Market Sale Agreement to offer and sell up to $100.0 million shares of common stock in at-the-market offerings; during 2023, the company sold 1,749,199 shares for net proceeds of $24.3 million . In August 2023, the company entered into agreements allowing the exercise of outstanding warrants in exchange for pre-funded warrants; all outstanding warrants were exercised for gross proceeds of $34.4 million in exchange for 44,748 shares of common stock and Pre-Funded Warrants to purchase 2,705,252 shares. In May 2024, the company amended its facility lease to extend the lease term and lease approximately 17,700 rentable square feet of additional office space. As of December 31, 2025, the company had 132 full-time equivalent employees, 103 of whom were in research and development.

License and collaboration revenue decreased by $388.4 million from $434.4 million for the year ended December 31, 2024 to $46.0 million for the year ended December 31, 2025. Net loss was $130.1 million for the year ended December 31, 2025, compared to net income of $275.2 million for the year ended December 31, 2024. Research and development expenses increased $21.2 million , or 15% , from $138.1 million for 2024 to $159.3 million for 2025. General and administrative expenses increased $1.4 million , or 3% , from $43.5 million for 2024 to $44.9 million for 2025. Interest income increased $2.5 million , or 9% , from $26.3 million for 2024 to $28.8 million for 2025. Income tax expense was $0.8 million and $4.2 million for 2025 and 2024, respectively. As of December 31, 2025, the company had an accumulated deficit of $470.7 million .

Business Outlook

A major growth vector is the potential regulatory approval and commercialization of Icotyde for moderate-to-severe plaque psoriasis. JNJ submitted an NDA to the FDA in July 2025 and an application to the EMA in September 2025, and JNJ has disclosed that it expects to launch Icotyde in the United States in 2026, subject to regulatory approval. The company is eligible to receive up to $630.0 million in future development and sales milestone payments from JNJ, including $50.0 million upon FDA approval of an NDA in any indication, $25.0 million upon acceptance of an NDA filing for a second indication, $45.0 million upon FDA approval for a second indication, $35.0 million upon acceptance of an NDA filing for a third indication, and $50.0 million upon FDA approval for a third indication. The company will also receive tiered royalties on net worldwide Icotyde product sales at percentages ranging from 6% to 10% , with a weighted average royalty rate of 7.25% on the first $4.0 billion in annual net sales and 10% on net sales over $4.0 billion . At JNJ's Enterprise Business Review in December 2023, JNJ highlighted Icotyde with potential peak year sales projected at greater than $5.0 billion .

Another major growth vector is the potential regulatory approval and commercialization of rusfertide for polycythemia vera. The company and Takeda submitted an NDA to the FDA in December 2025, and Takeda has disclosed that it expects to launch rusfertide in the second half of 2026, subject to regulatory approval. Rusfertide has received Orphan Drug status, Fast Track designation, and in August 2025, Breakthrough Therapy designation. The company expects to exercise its Full Opt-out Right in the second quarter of 2026, within the 90-day opt-out window beginning 120 days after the NDA filing date. If the opt-out right is exercised, the company will receive a $200.0 million payment following exercise and an additional $200.0 million payment following FDA approval, and will receive royalties of 14% to 29% on annual worldwide net sales, with a weighted average royalty rate of 21% at $1.5 billion in net sales and 29% for net sales over $1.5 billion . The company is eligible to receive up to an aggregate of $975.0 million in development, regulatory and sales milestones, including the $25.0 million milestone already received, and up to $400.0 million in payments for exercising the opt-out right. Upcoming potential milestones include $50.0 million upon FDA approval (or $75.0 million if the Full Opt-out Right is exercised), $15.0 million upon first regulatory approval in three European countries, and $10.0 million upon first regulatory approval in Japan.

The company expects research and development expenses to increase in the near term as compared to prior year periods as it continues to focus resources toward advancing pre-clinical and drug discovery research and clinical programs, including progressing product development candidates PN-881, PN-477, PN-458 and PN-8047 through IND-enabling studies. The company expects to complete the Phase 1 study of PN-881 in mid-2026 and initiate a Phase 2 study in psoriasis by the end of 2026. IND-enabling studies of PN-477 are underway with initiation of Phase 1 clinical studies in PN-477sc anticipated by mid-2026 and PN-477o in the second half of 2026. IND-enabling studies for PN-458o, PN-458sc, and PN-8047 are ongoing.

The company relies on third-party contract manufacturers for the manufacturing of its product candidates for pre-clinical studies and clinical trials and eventually for commercial supplies. The company does not own or operate any manufacturing facilities and has no plans to build any owned clinical or commercial scale manufacturing capabilities. The company has established a global supply chain for raw material, active pharmaceutical ingredients, drug product manufacturing and distribution, working with contract manufacturers in the United States, Europe and Asia. JNJ is responsible for the manufacturing of Icotyde pursuant to the JNJ License and Collaboration Agreement, and Takeda is responsible for the manufacturing of rusfertide pursuant to the Takeda Collaboration Agreement.

The company ended fiscal 2025 with cash, cash equivalents and marketable securities of approximately $646.0 million , compared to approximately $559.2 million as of December 31, 2024. Capital expenditures were $1.6 million , $1.4 million and $0.6 million for the years ended December 31, 2025, 2024 and 2023, respectively. Stock-based compensation was $45.974 million , $37.554 million and $29.293 million for the years ended December 31, 2025, 2024 and 2023, respectively. The company believes its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations for at least the next 12 months. The company has never declared or paid any cash dividends.

The company faces structural headwinds including the lengthy and expensive clinical development process with uncertain outcomes, and the risk that product candidates may cause undesirable side effects or have other properties adversely impacting safety that delay or prevent regulatory approval. The company has no approved products and no historical commercial revenue, making it difficult to assess future prospects. The company is heavily dependent on the success of its product candidates in clinical development, and failure can occur at any stage. The company relies on JNJ to develop Icotyde in additional indications and successfully commercialize it, and on Takeda to successfully commercialize rusfertide. The company may require additional funding, which may not be available on acceptable terms.

The company faces risks from unstable market and macroeconomic conditions, including tariffs or trade policy, which may have serious adverse consequences on its business, financial condition and stock price. In September 2025, the United States announced the imposition of up to 100% tariffs on imported branded or patented pharmaceuticals, subject to certain exceptions. The company also faces risks from disruptions at the FDA and other government agencies, including mass layoffs of federal employees since the start of the current presidential administration in January 2025, which could negatively affect the review of regulatory submissions.

Risk Factors

The company is heavily dependent on the success of its product candidates in clinical development, and if any of these products fail to receive regulatory approval or are not successfully commercialized, the business would be adversely affected. The company has no approved products and no historical commercial revenue, making it difficult to assess future prospects. Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies may not be predictive of future trial results. The company relies on JNJ to develop Icotyde in additional indications and successfully commercialize it, and on Takeda to successfully commercialize rusfertide; if either partner does not elect to continue development or successfully commercialize, the business would be adversely affected. The company has incurred a cumulative net loss since inception, with an accumulated deficit of $470.7 million as of December 31, 2025, and may incur significant losses in the future. The company may require additional funding, which may not be available on acceptable terms, and if required, there may be dilution to existing stockholders. The company faces significant competition from other biotechnology and pharmaceutical companies, and its operating results will suffer if it or its collaborators fail to compete effectively.

Management Priorities

Management's message emphasizes the company's position as an integrated discovery and development company with a validated technology platform, highlighting three broad therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Key strategic priorities include advancing Icotyde and rusfertide toward regulatory approval and commercialization, with JNJ submitting an NDA for Icotyde in July 2025 and the company and Takeda submitting an NDA for rusfertide in December 2025. Management also emphasizes advancing the wholly owned pipeline including PN-881, PN-477, PN-458, and PN-8047 through clinical development. The company expects to exercise its Full Opt-out Right under the Takeda Collaboration Agreement in the second quarter of 2026. Management believes the existing cash, cash equivalents and marketable securities of approximately $646.0 million will be sufficient to fund operations for at least the next 12 months.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Collaboration Agreements
  2. [2] Item 1, Business — Collaboration Agreements
  3. [3] Item 1, Business — Collaboration Agreements
  4. [4] Item 1, Business — Collaboration Agreements
  5. [5] Item 1, Business — Collaboration Agreements
  6. [6] Item 1, Business — Collaboration Agreements
  7. [7] Item 1, Business — Collaboration Agreements
  8. [8] Item 1, Business — Collaboration Agreements
  9. [9] Item 1, Business — Collaboration Agreements
  10. [10] Item 1, Business — Collaboration Agreements
  11. [11] Item 1, Business — Collaboration Agreements
  12. [12] Item 1, Business — Collaboration Agreements
  13. [13] Item 1, Business — Collaboration Agreements
  14. [14] Item 1, Business — Collaboration Agreements
  15. [15] Item 1, Business — Collaboration Agreements
  16. [16] Item 1, Business — Collaboration Agreements
  17. [17] Item 1, Business — Collaboration Agreements
  18. [18] Item 1, Business — Collaboration Agreements
  19. [19] Item 1, Business — Collaboration Agreements
  20. [20] Item 7, MD&A — Liquidity and Capital Resources
  21. [21] Item 7, MD&A — Liquidity and Capital Resources
  22. [22] Item 7, MD&A — Liquidity and Capital Resources
  23. [23] Item 7, MD&A — Liquidity and Capital Resources
  24. [24] Item 7, MD&A — Liquidity and Capital Resources
  25. [25] Item 7, MD&A — Liquidity and Capital Resources
  26. [26] Item 7, MD&A — Liquidity and Capital Resources
  27. [27] Item 7, MD&A — Liquidity and Capital Resources
  28. [28] Item 7, MD&A — Liquidity and Capital Resources
  29. [29] Item 7, MD&A — Liquidity and Capital Resources
  30. [30] Item 7, MD&A — Liquidity and Capital Resources
  31. [31] Item 2, Properties
  32. [32] Item 1, Business — Human Capital
  33. [33] Item 1, Business — Human Capital
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 7, MD&A — Results of Operations
  43. [43] Item 7, MD&A — Results of Operations
  44. [44] Item 7, MD&A — Results of Operations
  45. [45] Item 7, MD&A — Results of Operations
  46. [46] Item 7, MD&A — Results of Operations
  47. [47] Item 7, MD&A — Results of Operations
  48. [48] Item 7, MD&A — Results of Operations
  49. [49] Item 7, MD&A — Results of Operations
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Results of Operations
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Overview
  54. [54] Item 1, Business — Collaboration Agreements
  55. [55] Item 1, Business — Collaboration Agreements
  56. [56] Item 1, Business — Collaboration Agreements
  57. [57] Item 1, Business — Collaboration Agreements
  58. [58] Item 1, Business — Collaboration Agreements
  59. [59] Item 1, Business — Collaboration Agreements
  60. [60] Item 1, Business — Collaboration Agreements
  61. [61] Item 1, Business — Collaboration Agreements
  62. [62] Item 1, Business — Collaboration Agreements
  63. [63] Item 1, Business — Collaboration Agreements
  64. [64] Item 1, Business — Collaboration Agreements
  65. [65] Item 1, Business — Icotyde
  66. [66] Item 1, Business — Collaboration Agreements
  67. [67] Item 1, Business — Collaboration Agreements
  68. [68] Item 1, Business — Collaboration Agreements
  69. [69] Item 1, Business — Collaboration Agreements
  70. [70] Item 1, Business — Collaboration Agreements
  71. [71] Item 1, Business — Collaboration Agreements
  72. [72] Item 1, Business — Collaboration Agreements
  73. [73] Item 1, Business — Collaboration Agreements
  74. [74] Item 1, Business — Collaboration Agreements
  75. [75] Item 1, Business — Collaboration Agreements
  76. [76] Item 1, Business — Collaboration Agreements
  77. [77] Item 1, Business — Collaboration Agreements
  78. [78] Item 1, Business — Collaboration Agreements
  79. [79] Item 1, Business — Collaboration Agreements
  80. [80] Item 7, MD&A — Overview
  81. [81] Item 7, MD&A — Overview
  82. [82] Item 7, MD&A — Capital Requirements
  83. [83] Item 7, MD&A — Capital Requirements
  84. [84] Item 7, MD&A — Capital Requirements
  85. [85] Item 8, Note 11 — Equity Plans
  86. [86] Item 8, Note 11 — Equity Plans
  87. [87] Item 8, Note 11 — Equity Plans
  88. [88] Item 1A, Risk Factors
  89. [89] Item 1A, Risk Factors
  90. [90] Item 7, MD&A — Overview
  91. [91] Item 8, Consolidated Statements of Operations
  92. [92] Item 8, Consolidated Statements of Operations
  93. [93] Item 8, Consolidated Statements of Operations
  94. [94] Item 8, Consolidated Statements of Operations
  95. [95] Item 8, Consolidated Statements of Operations
  96. [96] Item 8, Consolidated Statements of Operations
  97. [97] Item 8, Consolidated Statements of Operations
  98. [98] Item 8, Consolidated Statements of Operations
  99. [99] Item 8, Consolidated Statements of Operations
  100. [100] Item 8, Consolidated Statements of Operations
  101. [101] Item 8, Consolidated Statements of Operations
  102. [102] Item 8, Consolidated Statements of Operations
  103. [103] Item 8, Consolidated Statements of Operations
  104. [104] Item 8, Consolidated Statements of Operations
  105. [105] Item 7, MD&A — Overview
  106. [106] Item 7, MD&A — Overview
  107. [107] Item 7, MD&A — Results of Operations
  108. [108] Item 7, MD&A — Results of Operations
  109. [109] Item 7, MD&A — Results of Operations
  110. [110] Item 7, MD&A — Results of Operations
  111. [111] Item 7, MD&A — Results of Operations
  112. [112] Item 8, Consolidated Balance Sheets

Analysis on 9/27/2026